HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases

Table 2 Cox regression analysis to identify prognostic factors for HBsAg loss in off-treatment patients

Variables	HR	95% CI	p-value
Male	1.674	0.244–11.475	0.600
Over 30 years old	0.703	0.095–5.183	0.730
Baseline ALT > 4 × ULN U/L	1.395	0.380–5.121	0.616
Baseline HBV DNA < 2 × 10⁶ IU/mL	0.097	0.007–1.379	0.085
Baseline HBsAg < 25,000 IU/mL	7.799	2.903–20.947	*< 0.001*
On-treatment HBsAg decline > 1 log₁₀ IU/mL at week 24	8.329	2.470–28.087	*0.001*
On-treatment HBV DNA decline > 2 log₁₀ IU/mL at week 24	12.726	0.627–258.244	0.098
Duration of IFN over 1 year	0.253	0.049–1.310	0.101
EOT HBsAg ≤10 IU/mL	7.918	2.453–25.556	*0.001*

ALT alanine aminotransferase, ULN upper limit of normal, IFN interferon, EOT end-of-treatment. P-values < 0.05 are shown in bold italics

ISSN: 1471-230X